Advancements in AUD Treatment: Precision Therapies and Future Growth Projections
Dublin, July 01, 2026 (GLOBE NEWSWIRE) -- The "Alcohol Use Disorder - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.
Alcohol Use Disorder (AUD) Insights and Trends
The United States has experienced a significant decline in AUD, including reductions in binge drinking and heavy alcohol use, especially among those aged 12-20. Estimates suggest approximately 25 million Americans are affected by AUD, indicating potential cultural norms around alcohol consumption. Despite this prevalence, treatment for AUD remains largely underutilized due to stigma and perceptions of ineffective treatments. Existing therapies often fail to provide long-term effectiveness, demonstrating the need for more potent options that can address both cravings and comorbid conditions. Current treatments include CAMPRAL, ANTABUSE, REVIA, and VIVITROL, with generics available for most, increasing accessibility.
Adial Pharmaceuticals is pioneering genetically targeted, oral precision therapy, AD04, currently in clinical trials and set to launch by 2028, promising enhanced drug efficacy and a personalized approach. The market lacks severity-specific treatments, though candidates like Sunobinop and Pemvidutide are under evaluation for moderate-to-severe AUD. The 2025 AUD market is valued at USD 1.10 billion, expected to grow to USD 3.60 billion by 2036 with a 12.1% CAGR.
Market Size and Forecast
The comprehensive 'Alcohol use disorder (AUD) - Market Insights, Epidemiology and Market Forecast - 2036' report delves into AUD trends in the US, EU4, UK, and Japan. It evaluates patient burden, market dynamics, therapy uptake, and unmet needs, providing a clear growth outlook. High unmet needs and the expanding treatable population, along with rising awareness, are key growth drivers.
Alcohol Use Disorder (AUD) Market Dynamics
High unmet needs, expanded treatable populations, and increased public awareness about alcohol's health risks underpin market growth. A shift towards targeted therapies, as exemplified by AD04's biomarker-based approach, anticipates enhanced treatment outcomes. The lack of predictive treatment tools, social stigma, and limited understanding of AUD's complexity also highlight significant challenges within the market.
Alcohol Use Disorder (AUD) Treatment Overview
AUD treatment encompasses behavioral therapies and medications, with cognitive-behavioral approaches and holistic interventions like mindfulness aiding recovery. However, current treatments exhibit limited effectiveness, underscoring the imperative for more innovative solutions. Efforts to improve AUD management extend to developing therapies that incorporate metabolic and neurological mechanisms, targeting unmet clinical needs. Market growth remains driven by the emergence of non-addictive, long-acting treatments like VIVITROL, and the potential success of pipeline therapies focusing on novel biological pathways.
AUD Drug Analysis and Market Outlook
VIVITROL, a leading market treatment, exemplifies an opioid receptor antagonist providing effective short-term management of alcohol dependence. Emerging therapies like AD04 by Adial Pharmaceuticals, designed as a precision therapeutic targeting AUD in genetically defined subgroups, highlight the shift towards personalized medicine. Eli Lilly's Brenipatide, investigating dual-receptor mechanisms, further emphasizes the broadening scope of therapy development in the AUD market.
Conclusion
Sustained market growth for AUD is bolstered by increasing awareness and innovative therapies addressing unmet needs. With a projected market size expansion, industry advancements are poised to deliver more efficacious, accessible, and personalized AUD treatments, fulfilling a critical need within the patient community.
Key Topics Covered:
1. Key Insights
2. Report Introduction
3. Executive Summary of Alcohol Use Disorder (AUD)
4. Key Events
4.1. Upcoming Key Catalysts
4.2. Key Transactions and Collaborations
4.3. News Flow
5. Epidemiology and Market Forecast Methodology
6. Alcohol Use Disorder (AUD) Market Overview at a Glance
6.1. Clinical Landscape (Analysis by Molecule Type, Phase, and Route of Administration [RoA])
6.2. Market Share of AUD by Therapies (%) in the US in 2025
6.3. Market Share of AUD by Therapies (%) in the US in 2036
7. Disease Background and Overview of Alcohol Use Disorder (AUD)
7.1. Introduction
7.2. Symptoms
7.3. Risk Factors
7.4. Pathophysiology
7.5. Types of Alcoholics
7.6. Diagnosis
7.7. Biomarkers
8. Treatment of Alcohol Use Disorder (AUD)
8.1. Treatment Guidelines of Alcohol Use Disorder (AUD)
8.1.1. New York State Department of Health AIDS Institute (NYSDOH AI) Recommendations for AUD (2023)
8.1.2. The Department of Veterans Affairs and the Department of Defense Guidelines for the Management of Substance Use Disorders (2021)
8.1.3. American Psychiatric Association (APA) Guidelines (2019)
9. Epidemiology and Patient Population of Alcohol Use Disorder (AUD)
9.1. Key Findings
9.2. Assumptions and Rationale
9.3. The United States
9.3.1. 12-months Diagnosed Prevalent Cases of AUD in the US
9.3.2. Gender-specific Diagnosed Prevalent Cases of AUD in the US
9.3.3. Age-specific Diagnosed Prevalent Cases of AUD in the US
9.3.4. Severity-specific Diagnosed Prevalent Cases of AUD in the US
9.3.5. Total Treated Cases of AUD in the US
9.4. EU4 and the UK
9.4.1. 12-months Diagnosed Prevalent Cases of AUD in EU4 and the UK
9.4.2. Gender-specific Diagnosed Prevalent Cases of AUD in EU4 and the UK
9.4.3. Age-specific Diagnosed Prevalent Cases of AUD in EU4 and the UK
9.4.4. Severity-specific Diagnosed Prevalent Cases of AUD in EU4 and the UK
9.4.5. Total Treated Cases of AUD in EU4 and the UK
9.5. Japan
9.5.1. 12-months Diagnosed Prevalent Cases of AUD in Japan
9.5.2. Gender-specific Diagnosed Prevalent Cases of AUD in Japan
9.5.3. Age-specific Diagnosed Prevalent Cases of AUD in Japan
9.5.4. Severity-specific Diagnosed Prevalent Cases of AUD in Japan
9.5.5. Total Treated Cases of AUD in Japan
10. Patient Journey of Alcohol Use Disorder (AUD)
11. Marketed Therapies
11.1. Marketed Competitive Landscape of Alcohol Use Disorder (AUD)
11.2. VIVITROL (naltrexone): Alkermes
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Summary of Pivotal Trials
11.2.5. Analyst's View
12. Emerging Therapies
12.1. Emerging Competitive Landscape of Alcohol Use Disorder (AUD)
12.2. AD04 (ondansetron): Adial Pharmaceuticals
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.3.1. Clinical Trials Information
12.2.4. Safety and Efficacy
12.2.5. Analyst's View
12.3. Brenipatide (LY3537031): Eli Lilly and Company
12.3.1. Product Description
12.3.2. Clinical Development
12.3.2.1. Clinical Trials Information
12.3.3. Analyst's View
12.4. MN-166 (ibudilast): MediciNova
12.4.1. Product Description
12.4.2. Other Developmental Activities
12.4.3. Clinical Development
12.4.3.1. Clinical Trials Information
12.4.4. Safety and Efficacy
12.4.5. Analyst's View
12.5. Sunobinop (V117957): Imbrium Therapeutics (subsidiary of Purdue Pharma)
12.5.1. Product Description
12.5.2. Other Developmental Activities
12.5.3. Clinical Development
12.5.3.1. Clinical Trials Information
12.5.4. Analyst's View
12.6. Pemvidutide: Altimmune
12.6.1. Product Description
12.6.2. Other Developmental Activities
12.6.3. Clinical Development
12.6.3.1. Clinical Trials Information
12.6.4. Analyst's View
12.7. TMP-301/HTL0014242: Tempero Bio and Nxera Pharma
12.7.1. Product Description
12.7.2. Other Developmental Activities
12.7.3. Clinical Development
12.7.3.1. Clinical Trials Information
12.7.4. Analyst's View
13. Alcohol Use Disorder (AUD): The US Market Analysis
13.1. Key Findings
13.2. Market Outlook
13.3. Conjoint Analysis
13.4. Key Market Forecast Assumptions
13.4.1. Cost Assumptions
13.5. The United States
13.5.1. Total Market Size of AUD in the US
13.5.2. Total Market Size of AUD by Therapies in the US
13.6. EU4 and the UK
13.6.1. Total Market Size of AUD in EU4 and the UK
13.6.2. Total Market Size of AUD by Therapies in EU4 and the UK
13.7. Japan
13.7.1. Total Market Size of AUD in Japan
13.7.2. Total Market Size of AUD by Therapies in Japan
14. Unmet Needs of Alcohol Use Disorder (AUD)
15. SWOT Analysis of Alcohol Use Disorder (AUD)
16. KOL Views of Alcohol Use Disorder (AUD)
16.1. Expert/KOL Interview Highlights
17. Market Access and Reimbursement of Alcohol Use Disorder (AUD)
17.1. The US
17.2. Market Access and Reimbursement of AUD Therapies
18. Appendix
18.1. Bibliography
18.2. Report Methodology
19. Publisher Capabilities
20. Disclaimer
21. About the Publisher
List of Tables
Table 1: Summary of AUD Market and Epidemiology (2025-2036)
Table 2: Upcoming Key Catalysts
Table 3: Key Transactions and Collaborations
Table 4: News Flow
Table 5: Interview Version
Table 6: 12-months Diagnosed Prevalent Cases of AUD in the US (2022-2036) (in Thousands)
Table 7: Gender-specific Diagnosed Prevalent Cases of AUD in the US (2022-2036) (in Thousands)
Table 8: Age-specific Diagnosed Prevalent Cases of AUD in the US (2022-2036) (in Thousands)
Table 9: Severity-specific Diagnosed Prevalent Cases of AUD in the US (2022-2036) (in Thousands)
Table 10: Total Treated Cases of AUD in the US (2022-2036) (in Thousands)
Table 11: Total Treated Cases of AUD in the US (2022-2036) (in Thousands)
Table 12: Comparison of Marketed Drugs
Table 13: Comparison of Emerging Drugs Under Development
Table 14: AD04 (ondansetron) Clinical Trial Description, 2026
Table 15: Brenipatide (LY3537031), Clinical Trial Description, 2026
Table 16: MN-166 (ibudilast) Clinical Trial Description, 2026
Table 17: Sunobinop (V117957), Clinical Trial Description, 2026
Table 18: Pemvidutide Clinical Trial Description, 2026
Table 19: TMP-301/HTL0014242 Clinical Trial Description, 2026
Table 20: Key Market Forecast Assumption of AUD in the US
Table 21: Total Market Size of AUD in the US, USD million (2022-2036)
Table 22: Total Market Size of AUD by Therapies in the US, USD million (2022-2036)
List of Figures
Figure 1: Treatment Algorithm for AUD
Figure 2: 12-months Diagnosed Prevalent Cases of AUD in the US (2022-2036)
Figure 3: Gender-specific Diagnosed Prevalent Cases of AUD in the US (2022-2036)
Figure 4: Age-specific Diagnosed Prevalent Cases of AUD in the US (2022-2036)
Figure 5: Severity-specific Diagnosed Prevalent Cases of AUD in the US (2022-2036)
Figure 6: Total Treated Cases of AUD in the US (2022-2036)
Figure 7: 12-months Diagnosed Prevalent Cases of AUD in EU4 and the UK (2022-2036)
Figure 8: Gender-specific Diagnosed Prevalent Cases of AUD in EU4 and the UK (2022-2036)
Figure 9: Age-specific Diagnosed Prevalent Cases of AUD in EU4 and the UK (2022-2036)
Figure 10: Severity-specific Diagnosed Prevalent Cases of AUD in EU4 and the UK (2022-2036)
Figure 11: Total Treated Cases of AUD in EU4 and the UK (2022-2036)
Figure 12: 12-months Diagnosed Prevalent Cases of AUD in Japan (2022-2036)
Figure 13: Gender-specific Diagnosed Prevalent Cases of AUD in Japan (2022-2036)
Figure 14: Age-specific Diagnosed Prevalent Cases of AUD in Japan (2022-2036)
Figure 15: Severity-specific Diagnosed Prevalent Cases of AUD in Japan (2022-2036)
Figure 16: Total Treated Cases of AUD in Japan (2022-2036)
Figure 17: Total Market Size of AUD in the US in USD million (2022-2036)
Figure 18: Total Market Size of AUD by Therapies in the US in USD million (2022-2036)
Figure 19: Health Technology Assessment
Figure 20: 7MM HTA bodies
Figure 21: US Healthcare Programs
Figure 22: Reimbursement Process of Germany
Figure 23: Reimbursement Process of France
Figure 24: Reimbursement Process of Italy
Figure 25: Reimbursement Process in Spain
Figure 26: Reimbursement Process in the United Kingdom
Figure 27: UK MHRA Approval Through IRF
Figure 28: Reimbursement Process in Japan
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this report visit https://www.researchandmarkets.com/r/2f5eq1
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.